ERAS
Erasca Inc
NASDAQ: ERAS · HEALTHCARE · BIOTECHNOLOGY
$9.11
-7.98% today
Updated 2026-04-29
Market cap
$6.68B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$1 – $24
Volume
6.9M
Erasca Inc (ERAS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-10.38M | $-32.69M | $-79.60M | $-103.26M | $-101.22M | $-109.42M | $-95.45M |
| Capital expenditures | $597000.00 | $38.69M | $18.89M | $16.55M | $1.77M | $22.56M | $128000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $122000.00 | $797000.00 | $8.33M | $20.11M | $26.23M | $26.97M | $24.90M |
| Free cash flow | $-10.97M | $-71.38M | $-98.48M | $-119.81M | $-102.99M | $-131.98M | $-95.58M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $295.21M | $-76.27M | — | — | — |